Mycobacterium Tuberculosis Malate Synthase Structures with Fragments Reveal a Portal for Substrate/Product Exchange

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2016 Oct 15

PMID 27738104

Citations 12

Authors

Hsiao-Ling Huang

Inna V Krieger

Maloy K Parai

Vijay B Gawandi

James C Sacchettini

Affiliations

Soon will be listed here.

Abstract

Fragment screening and high throughput screening are complementary approaches that combine with structural biology to explore the binding capabilities of an active site. We have used a fragment-based approach on malate synthase (GlcB) from Mycobacterium tuberculosis and discovered several novel binding chemotypes. In addition, the crystal structures of GlcB in complex with these fragments indicated conformational changes in the active site that represent the enzyme conformations during catalysis. Additional structures of the complex with malate and of the apo form of GlcB supported that hypothesis. Comparative analysis of GlcB structures in complex with 18 fragments allowed us to characterize the preferred chemotypes and their binding modes. The fragment structures showed a hydrogen bond to the backbone carbonyl of Met-631. We successfully incorporated an indole group from a fragment into an existing phenyl-diketo acid series. The resulting indole-containing inhibitor was 100-fold more potent than the parent phenyl-diketo acid with an IC value of 20 nm.

Citing Articles

and host interactions in the manifestation of tuberculosis.

Abbasnia S, Hashem Asnaashari A, Sharebiani H, Soleimanpour S, Mosavat A, Rezaee S J Clin Tuberc Other Mycobact Dis. 2024; 36:100458.

PMID: 38983441 PMC: 11231606. DOI: 10.1016/j.jctube.2024.100458.

Fragment-Based Drug Discovery against Mycobacteria: The Success and Challenges.

Togre N, Vargas A, Bhargavi G, Mallakuntla M, Tiwari S Int J Mol Sci. 2022; 23(18).

PMID: 36142582 PMC: 9500838. DOI: 10.3390/ijms231810669.

Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents.

Bajad N, Singh S, Singh S, Singh T, Singh M Curr Res Pharmacol Drug Discov. 2022; 3:100119.

PMID: 35992375 PMC: 9389259. DOI: 10.1016/j.crphar.2022.100119.

Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis.

Knoll K, Van der Walt M, Loots D Microbiol Spectr. 2022; 10(2):e0231521.

PMID: 35352998 PMC: 9045315. DOI: 10.1128/spectrum.02315-21.

An Overview of Genetic Information of Latent Mycobacterium tuberculosis.

Hamidieh F, Farnia P, Nowroozi J, Farnia P, Velayati A Tuberc Respir Dis (Seoul). 2020; 84(1):1-12.

PMID: 33121230 PMC: 7801807. DOI: 10.4046/trd.2020.0116.

References

Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

Sassetti C, Rubin E . Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A. 2003; 100(22):12989-94. PMC: 240732. DOI: 10.1073/pnas.2134250100. View

Lohman J, Olson A, Remington S . Atomic resolution structures of Escherichia coli and Bacillus anthracis malate synthase A: comparison with isoform G and implications for structure-based drug discovery. Protein Sci. 2008; 17(11):1935-45. PMC: 2578798. DOI: 10.1110/ps.036269.108. View

McKinney J, Honer zu Bentrup K, Munoz-Elias E, Miczak A, Chen B, Chan W . Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000; 406(6797):735-8. DOI: 10.1038/35021074. View

Schnappinger D, Ehrt S, Voskuil M, Liu Y, Mangan J, Monahan I . Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med. 2003; 198(5):693-704. PMC: 2194186. DOI: 10.1084/jem.20030846. View

Irwin J, Shoichet B . ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005; 45(1):177-82. PMC: 1360656. DOI: 10.1021/ci049714+. View

Rhee K, de Carvalho L, Bryk R, Ehrt S, Marrero J, Park S . Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier. Trends Microbiol. 2011; 19(7):307-14. PMC: 3601588. DOI: 10.1016/j.tim.2011.03.008. View

Erlanson D, Fesik S, Hubbard R, Jahnke W, Jhoti H . Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016; 15(9):605-619. DOI: 10.1038/nrd.2016.109. View

Chen H, Zhou X, Wang A, Zheng Y, Gao Y, Zhou J . Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Drug Discov Today. 2014; 20(1):105-13. PMC: 4305461. DOI: 10.1016/j.drudis.2014.09.015. View

10.

Hartshorn M, Murray C, Cleasby A, Frederickson M, Tickle I, Jhoti H . Fragment-based lead discovery using X-ray crystallography. J Med Chem. 2005; 48(2):403-13. DOI: 10.1021/jm0495778. View

11.

Ciulli A, Abell C . Fragment-based approaches to enzyme inhibition. Curr Opin Biotechnol. 2007; 18(6):489-96. PMC: 4441723. DOI: 10.1016/j.copbio.2007.09.003. View

12.

Scott D, Coyne A, Hudson S, Abell C . Fragment-based approaches in drug discovery and chemical biology. Biochemistry. 2012; 51(25):4990-5003. DOI: 10.1021/bi3005126. View

13.

Marrero J, Rhee K, Schnappinger D, Pethe K, Ehrt S . Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A. 2010; 107(21):9819-24. PMC: 2906907. DOI: 10.1073/pnas.1000715107. View

14.

Murray C, Carr M, Callaghan O, Chessari G, Congreve M, Cowan S . Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem. 2010; 53(16):5942-55. DOI: 10.1021/jm100059d. View

15.

Quartararo C, Blanchard J . Kinetic and chemical mechanism of malate synthase from Mycobacterium tuberculosis. Biochemistry. 2011; 50(32):6879-87. PMC: 3153559. DOI: 10.1021/bi2007299. View

16.

Kozakov D, Hall D, Jehle S, Jehle S, Luo L, Ochiana S . Ligand deconstruction: Why some fragment binding positions are conserved and others are not. Proc Natl Acad Sci U S A. 2015; 112(20):E2585-94. PMC: 4443342. DOI: 10.1073/pnas.1501567112. View

17.

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

18.

Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

19.

Anstrom D, Remington S . The product complex of M. tuberculosis malate synthase revisited. Protein Sci. 2006; 15(8):2002-7. PMC: 2242584. DOI: 10.1110/ps.062300206. View

20.

Saxty G, Woodhead S, Berdini V, Davies T, Verdonk M, Wyatt P . Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem. 2007; 50(10):2293-6. DOI: 10.1021/jm070091b. View